ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Virginie Baylot

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1313-2857; OpenAlex author ID A5046067066. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Faith Kivunga · 1 shared paper, 2026 · strength 0.30
- Paper Self-assembled nucleolipid G-quadruplexes act as multitarget decoys for oncogene suppression in pancreatic cancer DOI 10.1038/s41598-026-72237-z ↗
Philippe Barthélémy · 1 shared paper, 2026 · strength 0.30
- Paper Self-assembled nucleolipid G-quadruplexes act as multitarget decoys for oncogene suppression in pancreatic cancer DOI 10.1038/s41598-026-72237-z ↗
David Taïeb · 1 shared paper, 2011 · strength 0.02
- Paper OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. DOI 10.1038/cddis.2011.104 ↗
Palma Rocchi · 1 shared paper, 2011 · strength 0.02
- Paper OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. DOI 10.1038/cddis.2011.104 ↗
Juan Iovanna · 1 shared paper, 2011 · strength 0.02
- Paper OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. DOI 10.1038/cddis.2011.104 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.